Loading...

IKNA IKENA ONCOLOGY INC Investments/Divestments 8-K Filing

KN N

KN

IKENA ONCOLOGY INC

(IKNA)

2023 8-K

Show Summary

Summary

Merger of Equals

Merger of Equals

Merger of Equals

Merger Agreement

Appointment of Chief Operat...

Annual Meeting of Stockholders

Discontinuation of Clinical...

Resignation of Chief Medica...

Financial Results and Workf...

Financial Results and Clini...

Special Meeting Approval

Merger Agreement

Delisting Notice

Annual Meeting of Stockholders

Underwriting Agreement for ...

Preclinical Data Announcement

External Links:

Ikena Oncology, Inc. announced preclinical data on their investigational Hippo pathway inhibitor, IK-930, which showed selective inhibition of TEAD1 and potential for combination therapy in multiple cancer types.

AI Assistant

IKENA ONCOLOGY INC

2023

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.